ILYM19167, Reagan, mRNA-2752-P101, Lymphoma, mRNA-2752
Research Question:
Assess the safety and tolerability of escalating intratumoral doses of mRNA 2752 in
patients with relapsed/refractory solid tumor malignancies or lymphoma.
Basic Study Information
Purpose:
The clinical study will assess the safety and tolerability of escalating intratumoral
doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies
or lymphoma.
Location: University of Rochester Medical Center
Study Reference #: ILYM19167
Lead Researcher (Principal Investigator)
Lead Researcher:
Patrick Reagan
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search